Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16.8M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
1.45M
-
Shares change
-
-141K
-
Total reported value, excl. options
-
$11.2M
-
Value change
-
-$641K
-
Number of buys
-
7
-
Number of sells
-
-11
-
Price
-
$7.72
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q2 2025
29 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2025.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.45M shares
of 16.8M outstanding shares and own 8.64% of the company stock.
Largest 10 shareholders include Knoll Capital Management, LLC (631K shares), VANGUARD GROUP INC (455K shares), GEODE CAPITAL MANAGEMENT, LLC (121K shares), NORTHERN TRUST CORP (51K shares), BlackRock, Inc. (43.6K shares), CM Management, LLC (25K shares), STATE STREET CORP (21.6K shares), Quantinno Capital Management LP (20K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (17K shares), and MEYER HANDELMAN CO (13.9K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.